03/26/2020
One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from the recovered COVID-19 patients that are eligible to donate blood.
1. Prior diagnosis of COVID-19 documented by a laboratory test
2. Complete resolution of symptoms at least 14 days prior to donation
3. Female donors negative for HLA antibodies or male donors
4. Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood.
Eligible patients for use under expanded access provisions:
1. Must have laboratory confirmed COVID-19
2. Must have severe or immediately life-threatening COVID-19, for example:
3. Severe disease is defined as:
- dyspnea,
- respiratory frequency ≥ 30/min,
- blood oxygen saturation ≤ 93%,
- partial pressure of arterial oxygen to fraction of inspired
-oxygen ratio < 300, and/or
- lung infiltrates > 50% within 24 to 48 hours
Life-threatening disease is defined as:
respiratory failure,
septic shock, and/or
multiple organ dysfunction or failure
Must provide informed consent1.
It is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) might be effective against the infection.
Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2009-2010 H1N1 influenza virus pandemic, 2003 SARS-CoV-1 epidemic, and the 2012 MERS-CoV epidemic.
Although promising, convalescent plasma has not been shown to be effective in every disease studied. It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so.
One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from recovered COVID-19 patients. It is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) might be effective against the infection.